Research data indicated that HLA-G molecules in patients with MS treated with INF-β are also responsible for inhibiting the proliferation of CD4+ T cells or the production of pro-inflammatory cytokines by Th1 and Th2 lymphocytes. The gene discussed is CD4; the disease is myeloid sarcoma.